

ALLST

ALL STREET. TRANSFORMING RESEARCH



Assura Plc



Business Overview

ESTABLISHED: 2003

LOCATION: Warrington, Cheshire

LISTING: LSE

TYPE OF COMPANY: For profit

NUMER OF EMPLOYEES: 34

ISSUED SHARE CAPITAL:

1,649,816,418 ordinary shares of 10 pence¹

BUSINESS AREA:

Healthcare Real Estate Investment Trust

COMPANY WEBSITE:

www.assurapl.com

BUSINESS OVERVIEW

Assura Plc (“Assura”) is a UK based specialist healthcare property partner. The company works with general practitioners (GPs), health professionals and the National Health Service (NHS) to enable the delivery of patient care in the community through property solutions.

Assura plc operates in the Primary Care Property sector, which is a subsector of the Healthcare Property sector. The company invests in and develops property, and subsequently provides property management services for those premises.

Assura owns a core portfolio of 363 medical centers around the UK, valued at £1.2 billion².

SOCIAL MISSION

There is a growing consensus that primary care must play a bigger role in health provision in the UK. There has been significant historical underinvestment in primary care space and many GP premises are not currently fit for purpose. NHS England’s “General Practice Forward View”, announced in April 2016, further emphasises the need for appropriate primary care infrastructure and premises³.

Assura provides bespoke, purpose-built premises to satisfy the evolving needs of GPs as they look to meet the increasing health requirements of the UK population. Assura’s primary focus is to transform local communities by promoting health and wellbeing through development, investment, and management of efficient, extensive and high quality primary care healthcare properties.

WHO BENEFITS?

PATIENTS: Increased access to safe primary care facilities that provide integrated health services based on their needs. 3.7 million patients are registered to Assura-owned properties.

GPS AND OTHER HEALTHCARE PROVIDERS: Increased ability to meet the demands and needs of a changing patient population and changing regulatory requirements. An estimated 2,380 GPs work in Assura-owned properties⁴.

NHS: Increased provision of services through cost effective and convenient primary care setting. 18% of Assura’s income is from the NHS; 67% of its income is from GPs reimbursed by the NHS.

LOCAL ORGANISATIONS AND ECONOMY: Increased revenue and employment for local businesses as a result of portfolio development projects and ongoing maintenance work.

ENVIRONMENT: Minimised impact on the environment. Assura designs its buildings with a number of ecologically and environmentally sustainable features which typically make the new buildings more energy efficient.

¹ As at 30 September 2016

² As at 30 September 2016

³ Source: Interim results, November 2016

⁴ Source: Impact report, November 2016

Commercial and Financial Summary

CAPITAL STRUCTURE⁵

Assura is financed through both equity share capital and debt instruments, with total debt to capital standing at 62.2%.

PRICE CHART⁶



BUSINESS HIGHLIGHTS⁷

Assura Plc announced its half year results for the six months ended 30 September 2016.

CONTINUED GROWTH OF PORTFOLIO, RENTS AND PROFIT:

Net rental income increased 17% to £32.9 million in the period, underlying profit before tax increased by 75% to £19.8 million (2015: £11.3 million), investment property value increased by 10.6% to £1.2 billion (March 2016: £1.1 billion).

FINANCING: Assura strengthened its financial position by reducing its financing costs. In May 2016, Assura negotiated a new £200 million unsecured revolving credit facility, with a lower initial margin than the previous facility. In October 2016, the company signed agreements for its first US private placement, issuing new unsecured, ten-year notes totalling £100 million.

PIPELINE: Assura has a near term pipeline of further property acquisitions and developments of £131m.

The company's priorities include continuing to promote the case for investment in primary care and to develop its acquisition opportunities and pipeline.

FINANCIAL INFORMATION

(£m)	31-Mar-15	31-Mar-16	6m 30-Sept-16
Gross rental and related income	51.10	61.00	34.4
Profit before tax	36.60	28.80	41.7
EPS - basic	4.90p	2.20p	2.5p
Tangible Fixed Assets	927.10	1110.40	1,228.1
Shareholders' Funds	451.90	754.30	780.5
Cash Balances	66.50	44.30	27.7
Cash flow from operating activities	16.9	22.9	15.6
Quick Ratio ⁸	1.9	1.5	-
Loan to value	48%	30%	34%

FINANCIAL INFORMATION

TICKER: ASH

SHARE PRICE: 6.77p (close 31/12/16)

MARKET CAP: £4.05m⁹ (close 31/12/16)

⁵ Data as of Financial Year ending 30 September 2016, unless otherwise stated

⁶ Source: LSE

⁷ Data as of Financial Year ending 30 September 2016, unless

⁸ (Cash+Marketable Securities+Receivables/Current Liabilities)

⁹ LSE (The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly)

Impact Assessment Matrix

ECONOMIC IMPACT

	MEASUREMENT	REPORTED DATA		
Patients	Total area occupied by NHS and pharmacy tenants	2013/14 195,221sqm	2014/15 296,679sqm	2015/16 344,400sqm
	Total number of properties used to provide primary care services	2013/14 234	2014/15 301	2015/16 363
Health Budget	Average rental income per annum paid by NHS and pharmacy tenants	2013/14 £143,418	2014/15 £137,985	2015/16 £136,735
Local Economy	Value of development sites held for future development	2013/14 £8.69m	2014/15 £5.83m	2015/16 £3.85

ENVIRONMENTAL IMPACT

	MEASUREMENT	REPORTED DATA		
Sustainability	Percentage of new developments built on previously developed 'brownfield' sites	12 projects: 2013/14 71.43%	2014/15 75%	2015/16 75%
Waste Management	Average amount of non-hazardous construction waste generated per 100m ² Gross Internal Floor Area	6 BREEAM projects: 2013/14 3.23 tonnes	2014/15 5.52 tonnes	2015/16 5.52 tonnes
	Average percentage of construction waste diverted from landfill on Assura developments	5 BREEAM projects: 2013/14 85% by weight	2014/15 93.4% by weight	2015/16 93.4% by weight
Energy Consumption	Average percentage of construction waste diverted from landfill on Assura developments	6 BREEAM projects: 2013/14 35%	2014/15 24.97%	2015/16 24.97%

SOCIAL IMPACT

	MEASUREMENT	REPORTED DATA		
Patients	Number of patients registered to Assura-owned facilities	2013/14 2.27 million	2014/15 3.13 million	2015/16 3.72 million
Community Involvement	Average number of community engagement meetings hosted per project	8 projects: 2013/14 5	2014/15 4	2015/16 4
	Average number of community consultation surveys	8 projects: 2013/14 1	2014/15 1	2015/16 1

GOVERNANCE

	MEASUREMENT	REPORTED DATA
Corporate Governance	Executive Chairman	Yes
	Independent Non-Executive Directors	2
Diversity	% female employees	51%
	% female senior management	28%
	% female board	20%

MUST READ

This report has been commissioned by the Social Stock Exchange Limited and prepared by All Street Research Limited ("All Street Research").

All Street Research has produced this report in reliance on an exemption from the Financial Promotion Restriction to be found in article 20 of the Financial Services and Markets Act 2000 ("FSMA") (Financial Promotion) Order 2005.

For these purposes, All Street Research's reports and website are considered to be a publication or service that is a "qualifying publication" under that article and under article 54 of the Financial Services and Markets Act 2000 (Regulated Activities) Order 2001. It is therefore clearly understood that: No part of this research report amounts to the provision of investment advice specific to the investment circumstances of any user or other person.

This report is not to be construed as advice or recommendations to you specifically. This report is directed at individuals having sufficient investment sophistication to critically assess the information, analysis and opinion presented in herein. You should do your own due diligence, and take into account your personal financial circumstances and investment objectives, including your tolerance for risk, before investing.

By accepting this report you are deemed to warrant and to undertake that:

- (i) you are sufficiently expert to understand the risks involved with the investments to which this report relates; and
- (ii) you will comply with all applicable provisions of FSMA and the Financial Promotion Order with respect to anything you do in relation to this document.

If you are in any doubt about the investments to which this communication relates you should consult an authorised person who specialises in advising on this kind of investment

Provision of this report is not, in and of itself, intended to lead or to enable persons to invest. This report and any other materials on our website or publications should not be construed by any subscriber or prospective subscriber as a solicitation to effect, or attempt to effect, any transaction in a security. Use of All Street Research information available from this report is at your own risk. In no event will you hold All Street Research or any affiliated party liable for any direct or indirect trading or investment losses caused by any information on this document.

Trading involves risk, including possible loss of principal and other losses. All Street Research makes no representations that any of its materials will result in profits in trading. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings.

In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance.

This report is published solely for informational purposes and is made available on a complimentary basis. This report is based on publicly available information, together with information provided by the companies profiled in this report. Such information is presented "as is," and All Street Research cannot guarantee the adequacy, accuracy, completeness or timeliness of such information. Any forward-looking statements, opinions, views, subjective statements, and other commentary (together, "Subjective Statements") contained herein do not represent the views or opinions of All Street Research, but have been reproduced from publicly available third party sources, or from information supplied by the companies profiled herein. Such Subjective Statements contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. Any consensus forecasts provided herein have been reproduced in their entirety from publicly available information produced by third party data providers.

Cut-off dates have been applied to the information contained in the report such that some of the information published in the report may have changed between such cut-off dates, and the date of publication. Such changes may in some cases be material, such that there may be material differences between the current state and financial position of the companies and securities profiled herein, and the information presented herein. You should assume that all information that you review through this report is subject to change or updating at any time, and may be updated or deleted without warning or liability on our part. We may have previously distributed (and may in the future distribute) the information in these reports and analyses in different forms, including materially different or updated business, financial and market information in relation to the companies profiled herein.

Neither All Street Research nor any persons connected with All Street Research have any direct or indirect financial interest in any company that is reviewed in this report.

You agree that you will not communicate any content of this report to any other person unless that person has agreed to be bound by this Disclaimer. If you are acting as an agent for any other person, such person must also be identified by name to All Street Research. None of the material or any copy of it may be altered or distributed to any party without express written permission from All Street Research.